Status:

UNKNOWN

Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy

Lead Sponsor:

Cairo University

Conditions:

Psoriasis

Eligibility:

All Genders

12+ years

Phase:

NA

Brief Summary

• Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.

Eligibility Criteria

Inclusion

  • Patients with psoriasis (adults and children above 12years)
  • Both sexes.
  • New cases or cases not receiving any treatment for at least 3 months ago.

Exclusion

  • Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...)
  • Erythrodermic and pustular psoriasis.
  • History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Key Trial Info

Start Date :

March 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2018

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03483311

Start Date

March 1 2018

End Date

September 1 2018

Last Update

March 30 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maha Fathy Elmasry

Cairo, Egypt, 11562

Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy | DecenTrialz